BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

By uniting with publicly traded Aduro, Versant Ventures-incubated kidney company Chinook will gain a clinical asset for IgA nephropathy while also delivering liquidity to a VC syndicate that is committing additional capital to fund the...
BioCentury | Oct 11, 2019
Preclinical News

Oct. 10 Preclinical Quick Takes: Merck-Prokaryotics Inc.-Princeton ID new antibiotic class; plus NIH, Owkin, Genentech and ICR

Merck, Prokaryotics, Princeton ID new class of antibiotic Merck & Co. Inc. (NYSE:MRK), Prokaryotics Inc. and Princeton University researchers reported in a Proceedings of the National Academy of Sciences paper the identification of MRL-494, a...
BioCentury | Aug 17, 2019
Emerging Company Profile

Impact casting a wide synthetic lethality net

...through Chk1 and WEE1, leading to cell cycle arrest. ATM performs a similar function through Chk2...
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...through Chk1 and WEE1, leading to cell cycle arrest. ATM performs a similar function through Chk2...
...Ataxia telangiectasia and Rad3 related; Chk1 (CHEK1) - Checkpoint kinase 1; Chk2 (CHEK2) - Checkpoint kinase 2...
...Breast cancer 1 early onset Chk1 (CHEK1) - Checkpoint kinase 1 Chk2 (CHEK2) - Checkpoint kinase 2...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | May 17, 2019
Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support,...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
BioCentury | May 6, 2019
Distillery Therapeutics

PARG inhibition for ovarian cancer

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer Cell culture experiments suggest inhibiting PARG alone or in combination with Chk1 inhibitors could help treat ovarian cancer. In three human ovarian cancer cell lines, a tool compound PARG...
BioCentury | Mar 15, 2019
Product Development

Broadening the PARP playing field

...at least one inactivating mutation in a DDR gene, including BRCA1/2, ATM, Fanconi anemia genes, Chk2...
...BRCA1 - Breast cancer 1 early onset BRCA2 - Breast cancer 2 early onset Chk2 (CHEK2...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...and the hematopoiesis regulator LMO2 ( No. 674 ), and between DDR regulators Chk1 and Chk2...
...CCAAT enhancer binding protein α Chk1 (CHEK1) - Checkpoint kinase 1 Chk2 (CHEK2) - Checkpoint kinase 2...
Items per page:
1 - 10 of 97